COMPANY

Imbria Pharmaceuticals

Keywords: cardiovascular Non-obstructive Hypertrophic Cardiomyopathy Refractory Angina Type 2 Diabetes Diabetic Cardiomyopathies HFpEF - Heart Failure With Preserved Ejection Fraction Ischemia Coronary Artery Disease IMB-1018972

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$57.5MRaised (2 yrs)5Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · amount not disclosed · announced Nov 17, 2025 Company release ↗
Source quote
- Nov 17, 2025 · Company release ↗
  “(“Imbria”), a clinical-stage company developing transformational cardiovascular disease therapeutics, today announced the participation of AXA IM Alts in an upsized Series B financing, advancing the company’s mission to develop breakthrough solutions that address the world’s most urgent”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Nov 17, 2025 Raise Private equity round — Series B: amount not published, announced Nov 17, 2025. Source: company release on GlobeNewswire. source ↗
Nov 17, 2025 Raise Series B · amount not disclosed source ↗
Oct 6, 2025 Trial start Phase 2: A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy source ↗
Apr 10, 2025 Raise Private equity round — Series B: $57.5M (total, as published), announced Apr 10, 2025. Source: company release on GlobeNewswire. source ↗
Jun 14, 2021 Trial start Phase 2: A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial source ↗
Apr 23, 2021 Trial start Phase 2: Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia) source ↗
Apr 21, 2021 Trial start Phase 2: IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2) source ↗
May 1, 2020 Trial start Phase 2: A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 2 · A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy · NCT07023614

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $57.5M. Last 2 years.

Nov 17, 2025 Private equity round — Series B: amount not published, announced Nov 17, 2025. Source: company release on GlobeNewswire. source ↗
Apr 10, 2025 Private equity round — Series B: $57.5M (total, as published), announced Apr 10, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07023614	A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy	Phase 2	Recruiting	Oct 6, 2025	2026-12 (estimated)
NCT04306237	A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina	Phase 2	Withdrawn	May 1, 2020	2025-02 (estimated)
NCT04826159	IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)	Phase 2	Completed	Apr 21, 2021	Aug 6, 2024 (actual)
NCT04826172	Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)	Phase 2	Completed	Apr 23, 2021	Sep 21, 2023 (actual)
NCT04826185	A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial	Phase 2	Completed	Jun 14, 2021	Sep 18, 2023 (actual)